ArticleAmerican journal of clinical and experimental immunology2026
Expression and prognostic significance of CRKL in clear cell renal cell carcinoma.
Article in American journal of clinical and experimental immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma (ccRCC) is an aggressive kidney malignancy with limited prognostic biomarkers. CRKL has been implicated in cancer progression, but its prognostic value and immune associations in ccRCC remain unclear. Using TCGA, GEO, and UALCAN databases, we analyzed CRKL expression. Kaplan-Meier and multivariate Cox regression assessed survival; TIMER and TISIDB evaluated immune infiltration; LinkedOmics databases and GSEA identified enriched pathways. CRKL was significantly overexpressed in ccRCC tissues at both mRNA and protein levels. Surprisingly, high CRKL expression was associated with better overall survival (OS), disease-specific survival (DSS), progression-free interval (PFI), and disease free survival (DFS). Multivariate Cox analysis identified CRKL as an independent favorable prognostic factor (OS: HR = 0.469, 95% CI: 0.302-0.729, P < 0.001). CRKL positively correlated with immune cell infiltration and immune-related pathways. In conclusion, CRKL is overexpressed in ccRCC, paradoxically, higher expression predicts better prognosis and is associated with immune-active tumor microenvironment features. These findings suggest that the favorable prognosis associated with CRKL may be attributable to its immunomodulatory role within the tumor microenvironment, highlighting its potential as a novel prognostic biomarker for ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.